Journal article

Abiraterone in Metastatic Salivary Duct Carcinoma

Damien Urban, Danny Rischin, Christopher Angel, Ieta D'Costa, Benjamin Solomon

Journal of the National Comprehensive Cancer Network | HARBORSIDE PRESS | Published : 2015


Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy with limited evidence guiding standard treatment. SDC is known to overexpress the androgen receptor, with only a handful of cases reporting responses to androgen blockade. This report presents a case of SDC responding to multiple lines of androgen blockade, including a rapid response to abiraterone, a CYP17 inhibitor effective in prostate cancer. This case represents the first published report of SDC responding to abiraterone and illustrates that androgen receptor expressing SDC may be treated with multiple lines of androgen blockade, including newer agents such as abiraterone. This case suggests that SDC may conti..

View full abstract